NCT00960297View on ClinicalTrials.gov

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

May 31, 2013

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Carboplatin

Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64

DRUG

Paclitaxel

Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64

DRUG

Bevacizumab

Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)

Trial Locations (6)

33308

Holy Cross Hospital, Fort Lauderdale

37203

Tennessee Oncology, Nashville

40207

Norton Cancer Institute, Louisville

47802

Providence Medical Group, Terre Haute

49503

Grand Rapids Clinical Oncology Program, Grand Rapids

03801

Portsmouth Regional Hospital, Portsmouth

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER